Loqtorzi Market 2026–2035 expanding with immunotherapy advancements

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Loqtorzi Market During 2026–2030?

The historical expansion can be attributed to several factors, including increased rates of nasopharyngeal carcinoma diagnosis in regions where it is prevalent, progress in immunotherapy research, positive initial outcomes from PD-1 blockade trials, augmented funding for oncology research, and the growth in the number of specialized cancer centers.

During the projected period, the expansion can be linked to the increasing worldwide authorization of immunotherapy medications, a surge in investments for treating rare cancers, broader availability of oncology biologics, the expanding application of combination immunotherapies, and ongoing breakthroughs in immune modulation therapies. Key trends anticipated in this period encompass the greater integration of PD-1 inhibitors in rare cancer treatments, a heightened focus on managing nasopharyngeal carcinoma, the growth of immuno-oncology development pipelines, the rising implementation of immune checkpoint blockade therapies, and more vigorous global clinical trial engagement.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20148&type=smp

Which Economic Or Industry Drivers Are Impacting The Loqtorzi Market?

The increasing occurrence of nasopharyngeal carcinoma (NPC) is anticipated to drive the expansion of the loqtorzi market in the future. Nasopharyngeal carcinoma is a cancer that affects the nasopharynx and is closely linked to Epstein-Barr virus infection, with early diagnosis significantly impacting treatment outcomes. The rising incidence of nasopharyngeal carcinoma can be attributed to factors such as elevated exposure to the Epstein-Barr virus, genetic predisposition, environmental elements like tobacco and alcohol use, and dietary habits, particularly the consumption of salted and preserved food. Loqtorzi (toripalimab) aids nasopharyngeal carcinoma (NPC) patients by boosting the immune system’s capacity to attack cancer cells through the inhibition of the PD-1 pathway, thereby offering an innovative therapeutic choice for individuals with recurrent or metastatic NPC, either in combination with chemotherapy or as a monotherapy after disease progression. For example, Cancer Research UK, a registered charity based in the UK, indicated in October 2024 that head and neck cancer incidence in the UK is projected to rise by 3% when comparing the period 2023–2025 with 2038–2040. Consequently, the increased prevalence of nasopharyngeal carcinoma is a key factor propelling the growth of the loqtorzi market.

How Are The Various Segments Of The Loqtorzi Market Categorized?

The loqtorzi market covered in this report is segmented –

1) By Formulation: Injectable Formulation (intravenous), Lyophilized Powder For Reconstitution

2) By Indication: Treatment Of Small Cell Lung Cancer (SCLC), Treatment Of Other Solid Tumors

3) By Patient Demographics: Adult Patients, Geriatric Patients, Pediatric Patients

4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals, Oncology Clinics, Specialty Pharmacies, Research Institutions

What Trends Are Affecting The Expansion Of The Loqtorzi Market?

A significant trend within the Loqtorzi market involves concentrating on the development of biosimilars to expand product portfolios and provide more economical treatment options as alternatives to biologic therapies. Biosimilars are biological products that are highly similar to an approved reference product, lacking any clinically meaningful distinctions in safety or effectiveness. These offer an affordable substitute for expensive biologic drugs once the original product’s patent expires. For instance, in November 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, launched a biosimilar version of Coherus BioSciences’ (CHRS) Loqtorzi (toripalimab) in India under the brand name Zytorvi. This drug is indicated for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a rare form of cancer. Loqtorzi received FDA approval in October 2023 for the first-line treatment of RM-NPC when used in combination with cisplatin and gemcitabine, and as a monotherapy for patients experiencing disease progression after platinum-based chemotherapy. It is recognized as the only FDA-approved immuno-oncology drug for this specific indication.

Which Major Firms Influence Developments In The Loqtorzi Market?

Major companies operating in the loqtorzi market are Coherus BioSciences Inc., Shanghai Junshi Biosciences Co. Ltd.

Read the full loqtorzi market report here:

https://www.thebusinessresearchcompany.com/report/loqtorzi-global-market-report

What Are The Top-Performing Regions Within The Loqtorzi Market?

North America was the largest region in the loqtorzi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the loqtorzi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Loqtorzi Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20148&type=smp

Browse Through More Reports Similar to the Global Loqtorzi Market 2026, By The Business Research Company

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795